Close Menu

NEW YORK (GenomeWeb News) – Horizon Discovery and biopharmaceutical firm H3 Biomedicine today announced a collaboration to identify and validate a panel of novel cancer drug targets.

The firms will partner to carry out experiments that seek to identify cancer genome targets. H3 will carry out early target discovery through pre-clinical research, and Horizon will use its drug discovery tools "to run alongside and support [H3's] discovery biology and chemistry assets and capabilities," the partners said.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

The American Prospect writes that the pilot program to test the DNA of migrants could lead to more family separations.

An international commission is to develop a report on how researchers, clinicians, and regulators should evaluate the clinical applications of human germline genome editing.

The US Department of Agriculture presents a new blueprint for animal genomic research.

In Genome Research this week: repetitive element deletion linked to altered methylation and more in form of muscular dystrophy; human contamination in draft bacterial and archaeal genomes; and more.